Evaluating Sex Differences in GLP-1 and SGLT2i Effects on Heart-Kidney-Metabolism
Background
The complex condition of Cardiovascular-Kidney-Metabolic Health (CKMH) syndrome encompasses interconnected disorders like type 2 diabetes, heart failure, and chronic kidney disease, representing a significant global health challenge. Medications such as GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is) have shown remarkable benefits in improving CKMH outcomes. However, there is a crucial knowledge gap regarding how the effectiveness of these powerful drugs might differ between male and female patients in real-world settings.
Results
As this is an ACTIVE_NOT_RECRUITING study (NCT07188545) with an estimated completion date of 2029-06-30, there are no actual findings to report yet. However, the study aims to uncover critical real-world data on sex-based differences in treatment efficacy. The primary objective is to quantify how GLP-1RAs and SGLT2is impact cardiovascular, kidney, and metabolic health outcomes differently in men versus women. > This research is designed to identify and quantify sex-specific differences in the effectiveness of GLP-1RAs and SGLT2is on CKMH outcomes, analyzing an estimated 23.28 million patient records. The study will compare the incidence of major adverse cardiovascular events, kidney function decline, and improvements in metabolic parameters between sexes, for both the intervention and comparator drug classes. It is anticipated that the analysis will reveal specific patient subgroups that may benefit more or less from these therapies based on sex, providing quantitative insights into these disparities.
Why It Matters
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines for GLP-1RAs and SGLT2is, ensuring more effective and safer treatments for millions. This large-scale real-world data analysis has the potential to inform clinical practice and future drug development, highlighting the importance of considering biological sex in treatment strategies. The findings, once available after the study's completion in 2029, will pave the way for more targeted interventions and potentially influence future Phase II and III human trials.